|

68Ga-N188 PET/CT Imaging in Malignancy

RECRUITINGN/ASponsored by Peking University First Hospital
Actively Recruiting
PhaseN/A
SponsorPeking University First Hospital
Started2022-08-12
Est. completion2025-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05593107

Summary

The Nectin-4 protein belongs to the cell adhesion factors family and has a tissue-specific expression spectrum in normal human tissues. However, Nectin-4 is overexpressed in various malignancies, especially those of epithelial origins, such as uroepithelial carcinoma, making Nectin-4 a highly specific and significant imaging target for malignancies. \[68Ga\]N188, a novel molecular probe of PET imaging agent that targets Nectin-4, can be used in the diagnosis and research of a wide variety of Nectin-4 high-expression malignancies, including bladder cancer.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* patients with confirmed or suspected cancer;
* 18F-FDG PET/CT within 1 week;
* Signed written informed consent.

Exclusion Criteria:

* Pregnant and lactating women;
* Female patients plan to become pregnant within 6 months.

Conditions2

CancerNeoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.